Table 2 Treatment regimen and outcomes of MR-MAC-PD
Study | N | Treatment regimen, n (%) | FQ, n (%) | AG, n (%) | CFZ, n(%) | Surgery, n (%) | Treatment duration, months |
Tanaka 1999 [13] | 6 | NA | NA | NA | NR | NR | NA |
Griffith 2006 [5] | 51 | Surgery, prolonged (≥6 mo) AG: 14 (27) Surgery, no prolonged AG: 2 (4) No surgery, prolonged AG: 8 (16) No surgery, no prolonged AG: 27 (53) | CIPX 4 (8) GTFX 6 (12) | SM 24 (47) AMK 11 (22) | 4 (8) | 16 (31) | NA* |
Moon 2016 [6] | 34 | Macrolide 16 (47), EMB 25 (74), RIF or RFB 34 (100) | MFX 17 (50) | SM 13 (38) | 4 (12) | 2 (6) | 23.0 (16.8–45.3) |
Morimoto 2016 [7] | 90 | CAM 55 (61), RFB 15 (17) FQ 56 (62) for median 12 mo AG 52 (58) for median 6 mo | STFX 44 (49) MFX 11 (12) LFX 8 (9) | AMKi 32 (36) AMKn 7 (8) KM 10 (11) SM 4 (4) | NR | 11 (12) | 21 (10–37) |
Kadota 2016 [8] | 33 | CAM 24 (73), AZM 2 (6), Regimen without macrolide 7 (21) FQ for median 5 mo | LFX 16 (48) MFX 2 (6) STFX 2 (6) | KM 9 (27) | NR | 0 (0) | 10.4 ± 1.6¶ |
Yagi 2017 [14] | 9 | RIF + EMB + FQ + AMKn: 4 (44) RIF (RFB) + FQ + AMKn: 2 (22) EMB + FQ + AMKn: 1 (11) RIF + EMB + AMKn: 1 (11) CAM + EMB + AMKn: 1 (11) | STFX 6 (67) MFX 1 (11) | AMKn 9 (100) | 0 (0) | 0 (0) | (6–16)# |
Aznar 2018 [15] | 8 | All patients received GBT, including a macrolide, ethambutol, and a rifamycin when possible. Four patients had adjuvant surgery. | NA | NA | NA | 4 (50) | > 12 |
Griffith 2018 [16] | 73 | Patients were randomly assigned in a 2:1 ratio to receive ALIS to GBT or GBT alone. | NA | ALIS 51 (70) | NA | NA | NA |
Asakura 2019 [17] | 15 | GBT plus STFX 200 mg 14 (93) GBT plus STFX 100 mg 1 (7) | STFX 15 (100) | AMKi or AMKn 5 (33) | NR | 2 (13) | ≥12 mo: 13 (87%) < 12 mo: 2 (13%) |
Study | N | Sputum culture conversion definition | Conversion, n (%) | Mortality, n (%) | Follow-up duration, months | ||
Tanaka 1999 [13] | 6 | Consecutive negative cultures during a 3-month period | 1 (17) | NR | NA | ||
Griffith 2006 [5] | 51 | A minimum of three consecutive negative cultures over a minimum time of three months | 13 (26) | 1-yr 13 (25) 2-yr 17 (33) | (16–84)† (18–54)‡ | ||
Moon 2016 [6] | 34 | Three consecutive negative cultures, 2- to 3-month intervals | 5 (15)§ | 1-yr 3 (9) 3-yr 8 (24) 5-yr 16 (47) | 39.3 (22.9–43.4) | ||
Morimoto 2016 [7] | 90 | Three consecutive negative cultures | 10 (11) | 1-yr 8 (9) 2-yr 13 (15) 3-yr 15 (17) 5-yr 26 (29) | 21 (10–37) | ||
Kadota 2016 [8] | 33 | Two consecutive negative cultures. If the patient could not expectorate sputum, it was considered to have converted to negative | 12 (36) | 1-yr 2 (6) | 10.4 ± 1.6¶ | ||
Yagi 2017 [14] | 9 | Three consecutive negative cultures after amikacin inhalation | 3 (33) | NR | NR | ||
Aznar 2018 [15] | 8 | Persistently negative cultures or when unable to provide sputum specimens for culture during at least 12 months | 3 (38) | 1-yr 0 (0) | > 12 | ||
Griffith 2018 [16] | 73 | Three consecutive monthly MAC-negative cultures by Month 6 | 8 (11) | NR | 6** | ||
Asakura 2019 [17] | 15 | Three consecutive negative cultures. If the patients did not expectorate sputum, the status was recorded as negative. | 6 (40) | NA | NA |